Judith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Judith Kulich
Advertisement
Articles by Judith Kulich
Three product launch trends driven by emerging biopharma.
Advertisement
Latest Updated Articles
Is the Tail Wagging the Dog in Drug Market Entry?Published: January 13th 2020 | Updated:
Adapting Biopharma Launches in the COVID-19 LandscapePublished: April 7th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
